Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Imatinib therapy, which targets the oncogene product BCR-ABL, has transformed chronic myeloid leukemia (CML) from a life-threatening disease into a chronic condition. Most patients, however, harbor residual leukemia cells, and disease recurrence usually occurs when imatinib is discontinued. Although various mechanisms to explain leukemia cell persistence have been proposed, the critical question from a therapeutic standpoint--whether disease persistence is BCR-ABL dependent or independent--has not been answered. Here, we report that human CML stem cells do not depend on BCR-ABL activity for survival and are thus not eliminated by imatinib therapy. Imatinib inhibited BCR-ABL activity to the same degree in all stem (CD34+CD38-, CD133+) and progenitor (CD34+CD38+) cells and in quiescent and cycling progenitors from newly diagnosed CML patients. Although short-term in vitro imatinib treatment reduced the expansion of CML stem/progenitors, cytokine support permitted growth and survival in the absence of BCR-ABL activity that was comparable to that of normal stem/progenitor counterparts. Our findings suggest that primitive CML cells are not oncogene addicted and that therapies that biochemically target BCR-ABL will not eliminate CML stem cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Even potent TKIs are unable to eradicate CML-LSCs,6,7 which are the main culprit of disease relapse upon TKI discontinuation.”
From Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia (2024) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Ki-67 protein: From the known and the unknown
Scholzen, T., & Gerdes, J. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200003)182:3<311::aid-jcp1>3.0.co;2-9 · Cited by 4,646 · cited 1×
“To clarify this question, we analyzed BCR-ABL activity in imatinib-treated quiescent CML cells using Ki-67 negativity as a marker of quiescence (37).”
MethodFive-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488 · cited 3×
“Newly diagnosed patients with chronic phase CML have an almost 90% chance of being alive at 60 months after diagnosis (2).”
BackgroundSelf-citationClinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Zhou, S., Schuetz, J. D., Bunting, K. D., Colapietro, A.-M., Sampath, J., Morris, J. J., Lagutina, I., Grosveld, G. C., Osawa, M., Nakauchi, H., et al. (2001) · Nature Medicine · doi:10.1038/nm0901-1028 · Cited by 2,280 · cited 2×
“Enhanced expression of the drug efflux pumps breast cancer resistance protein (10) and P-glycoprotein (11) in CML stem cells may reduce sensitivity to imatinib by lowering intracellular imatinib concentrations (12–15).”
BackgroundAC133, a Novel Marker for Human Hematopoietic Stem and Progenitor Cells
Yin, A. H., Miraglia, S., Zanjani, E. D., Almeida-Porada, G., Ogawa, M., Leary, A. G., Olweus, J., Kearney, J., & Buck, D. W. (1997) · Blood · doi:10.1182/blood.v90.12.5002 · Cited by 1,822
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
The molecular biology of chronic myeloid leukemia
Deininger, M. W. N., Goldman, J. M., & Melo, J. V. (2000) · Blood · doi:10.1182/blood.v96.10.3343 · Cited by 1,667 · cited 2×
“Introduction Chronic myeloid leukemia (CML) originates in a HSC with the reciprocal translocation t(9;22) (1).”
BackgroundSelf-citationCharacterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492 · cited 1×
“Introduction Chronic myeloid leukemia (CML) originates in a HSC with the reciprocal translocation t(9;22) (1).”
BackgroundHughes, T. P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M. L., Gathmann, I., Bolton, A. E., van Hoomissen, I. C., Goldman, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030513 · Cited by 1,218 · cited 4×
“Those whose disease is undetectable by RT-PCR usually experience recurrence of active leukemia when imatinib therapy is discontinued (4, 5), which indicates that leukemic cells persist in most patients even when the disease burden is reduced below detectable limits.”
BackgroundInfluentialGraham, S. M., Jørgensen, H. G., Allan, E., Pearson, C., Alcorn, M. J., Richmond, L., & Holyoake, T. L. (2002) · Blood · doi:10.1182/blood.v99.1.319 · Cited by 1,181 · cited 6×
“In accord with previous reports (19), we observed that primitive noncycling BCR-ABL–positive cells”
BackgroundResultInfluential
Cited by
Items 101–200 of 799
The Bone Marrow Microenvironment as Niche Retreats for Hematopoietic and Leukemic Stem Cells
Nwajei, F., & Konopleva, M. Y. (2013) · Advances in Hematology · doi:10.1155/2013/953982 · Cited by 103
“In contrast, quiescent leukemia cells are resistant to imatinib therapy [59, 60].”
BackgroundArranz, L., Arriero, M. D. M., & Villatoro, A. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.05.001 · Cited by 95
The Role of IL-33-Dependent Inflammation in the Tumor Microenvironment
Wasmer, M.-H., & Krebs, P. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00682 · Cited by 90
“For instance, combination of imatinib and IL-33 blockade in CML may allow elimination of cytokine-dependent malignant stem cells (118) or prevent the emergence of drug resistance (101).”
BackgroundCasetti, L., Martin‐Lannerée, S., Najjar, I., Plo, I., Augé, S., Roy, L., Chomel, J., Lauret, E., Turhan, A. G., & Dusanter‐Fourt, I. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3955 · Cited by 84
Cheloni, G., Tanturli, M., Tusa, I., Ho DeSouza, N., Shan, Y., Gozzini, A., Mazurier, F., Rovida, E., Li, S., & Dello Sbarba, P. (2017) · Blood · doi:10.1182/blood-2016-10-745588 · Cited by 85
“Despite its effect on cell bulk, IM did not affect LC2 repopulation (Figure 3B), as we previously reported,4,5 in keeping with the refractoriness of LSC to TKi.2,3,6 ACF completely suppressed LC2 repopulation, irrespectively of the presence or absence of IM (Figure 3B).”
ResultInfluentialTargeted drug delivery for tumor therapy inside the bone marrow
Mu, C., Shen, J., Liang, J., Zheng, H., Xiong, Y., Wei, Y., & Li, F. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.11.029 · Cited by 86
Irvine, D. A., Zhang, B., Kinstrie, R., Tarafdar, A., Morrison, H., Campbell, V. L., Moka, H. A., Ho, Y., Nixon, C., Manley, P. W., et al. (2016) · Scientific Reports · doi:10.1038/srep25476 · Cited by 81
Sobrinho-Simões, M. A., Wilczek, V. J., Score, J., Cross, N. C. P., Apperley, J. F., & Melo, J. V. (2010) · Blood · doi:10.1182/blood-2009-11-255109 · Cited by 83
“Recent evidence suggests that imatinib does inhibit Bcr-Abl activity in primitive CML cells, and that their survival is Bcr-Abl-independent.(109)”
BackgroundCurrent aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia
Balabanov, S., Braig, M., & Brümmendorf, T. H. (2014) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2014.03.003 · Cited by 83
Chronic Myeloid Leukemia: Beyond BCR-ABL1
Zhou, T., Medeiros, L. J., & Hu, S. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0474-6 · Cited by 90
Horne, G. A., Stobo, J., Kelly, C., Mukhopadhyay, A., Latif, A. L., Dixon-Hughes, J., McMahon, L., Cony‐Makhoul, P., Byrne, J., Smith, G., et al. (2020) · Leukemia · doi:10.1038/s41375-019-0700-9 · Cited by 78
Morotti, A., Panuzzo, C., Crivellaro, S., Pergolizzi, B., Familiari, U., Berger, A. H., Saglio, G. N., & Pandolfi, P. P. (2013) · Leukemia · doi:10.1038/leu.2013.370 · Cited by 79
Chen, M., Gallipoli, P., DeGeer, D., Sloma, I., Forrest, D. L., Chan, M. M. K., Lai, D., Jørgensen, H. G., Ringrose, A., Wang, H. M., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt006 · Cited by 76
The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells
Zhang, H., Peng, C., Hu, Y., Li, H., Sheng, Z., Chen, Y., Sullivan, C., Černý, J., Hutchinson, L., Higgins, A. W., et al. (2012) · Nature Genetics · doi:10.1038/ng.2350 · Cited by 85
Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes
Stagno, F., Stella, S., Spitaleri, A., Pennisi, M. S., Raimondo, F. D., & Vigneri, P. G. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1151356 · Cited by 74
“apoptotic effect when exposed to IM despite the inhibition of BCR-ABL activity [19].”
BackgroundIdentification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML
Sadovnik, I., Hoelbl‐Kovacic, A., Herrmann, H., Eisenwort, G., Cerny‐Reiterer, S., Warsch, W., Hoermann, G., Greiner, G., Blatt, K., Peter, B., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0767 · Cited by 74
Low Doses of Imatinib Induce Myelopoiesis and Enhance Host Anti-microbial Immunity
Napier, R. J., Norris, B. A., Swimm, A. I., Giver, C. R., Harris, W. A. C., Laval, J., Napier, B. A., Patel, G., Crump, R., Peng, Z., et al. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1004770 · Cited by 76
“However, the drug does not appear to affect survival of Ph hematopoietic stem cells (HSCs), nor of Ph cells [9].”
BackgroundAiriau, K., Mahon, F., Josselin, M., Jeanneteau, M., & Belloc, F. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.309 · Cited by 73
“However, it was inefficient to induce apoptosis in CD34þ /CD38 CML cells which were also resistant to BCR-ABL inhibition.(10,28) Conversely, the PI3K inhibitors alone were able to induce apoptosis in CD34þ /CD38 CML stem cells, illustrating different survival mechanisms in progenitors and stem cells (Figure 6).”
BackgroundInfluentialLandberg, N., von Palffy, S., Askmyr, M., Lilljebjörn, H., Sandén, C., Rissler, M., Mustjoki, S. M., Hjorth‐Hansen, H., Richter, J., Ågerstam, H., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.169946 · Cited by 75
Rinke, J., Chase, A., Cross, N. C. P., Hochhaus, A., & Ernst, T. (2020) · Cells · doi:10.3390/cells9071639 · Cited by 79
“Previous studies have concluded that CML LSCs are not “oncogene-addicted” and serve as a reservoir to drive relapse or resistance; thus, merely targeting BCR-ABL1 kinase activity using TKI would not eliminate them, which necessitates combined treatment strategies [86,87].”
BackgroundMengistu, B. A., Tsegaw, T., Demessie, Y., Getnet, K., Bitew, A. B., Kinde, M. Z., Berihun, A. M., Mebratu, A. S., Mekasha, Y. T., Feleke, M. G., et al. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03558-0 · Cited by 85
Calabretta, B., & Salomoni, P. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.546913 · Cited by 76
“Although it is still controversial whether TKIs can suppress BCR–ABL activity in Ph(1) stem cells [21,22,25], a recent study provides strong evidence in support of IM being able to inhibit the tyrosine kinase activity of BCR–ABL in CML stem cells [27]; however, this study also showed that cytokine support allowed Ph(1…”
ResultConcise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment
Arrigoni, E., Re, M. D., Galimberti, S., Restante, G., Rofi, E., Crucitta, S., Baratè, C., Petrini, M., Danesi, R., & Paolo, A. D. (2018) · Stem Cells Translational Medicine · doi:10.1002/sctm.17-0175 · Cited by 73
Koschmieder, S., & Vetrie, D. L. P. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.07.006 · Cited by 76
“minimal residual disease is maintained by a sub-population of LSC[17] in the bone marrow (referred to as LSC persistence) [18-21] which are TKI-resistant [22-24] and can serve as a reservoir for disease relapse if TKI therapy is discontinued.”
BackgroundThe controversial role of the Hedgehog pathway in normal and malignant hematopoiesis
Mar, B. G., Amakye, D. D., Aifantis, I., & Buonamici, S. (2011) · Leukemia · doi:10.1038/leu.2011.143 · Cited by 78
McCormack, P. L., & Keam, S. J. (2011) · Drugs · doi:10.2165/11207580-000000000-00000 · Cited by 76
“While dasatinib inhibits an earlier progenitor population of CML cells than imatinib or nilotinib,([20]) primitive CML stem cells are capable of surviving despite BCR-ABL inhibition with imatinib,([21]) and this is likely to also be the case with dasatinib and nilotinib, indicating the likely need for life-long contin…”
Mustjoki, S. M., Richter, J. R., Barbany, G., Ehrencrona, H., Fioretos, T., Gedde‐Dahl, T., Gjertsen, B. T., Hovland, R., Hernesniemi, S., Josefsen, D., et al. (2013) · Leukemia · doi:10.1038/leu.2013.19 · Cited by 68
The IL-2/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells
Kobayashi, C. I., Takubo, K., Kobayashi, H., Nakamura‐Ishizu, A., Honda, H., Kataoka, K., Kumano, K., Akiyama, H., Sudo, T., Kurokawa, M., et al. (2014) · Blood · doi:10.1182/blood-2013-07-517847 · Cited by 73
“CML therapy with tyrosine kinase inhibitors (TKIs) is highly effective, but not curative in a majority of patients, presumably due to the insensitivity of CML leukemia-initiating cells (LICs) to TKIs.2 Although CML CP is now controllable, the cessation of TKI treatment in patients with major molecular remission usuall…”
BackgroundAgarwal, P., Zhang, B., Ho, Y., Cook, A., Li, L., Mikhail, F. M., Wang, Y., McLaughlin, M. E., & Bhatia, R. (2017) · Blood · doi:10.1182/blood-2016-05-714089 · Cited by 70
Kinstrie, R., Horne, G. A., Morrison, H., Irvine, D., Munje, C., Castañeda, E. G., Moka, H. A., Dunn, K., Cassels, J. E., Parry, N., et al. (2020) · Leukemia · doi:10.1038/s41375-019-0684-5 · Cited by 67
Autophagy in blood cancers: biological role and therapeutic implications
Nencioni, A., Cea, M., Montecucco, F., Longo, V. D., Patrone, F., Carella, A. M., Holyoake, T. L., & Helgason, G. V. (2013) · Haematologica · doi:10.3324/haematol.2012.079061 · Cited by 71
Chomel, J., Bonnet, M. L., Sorel, N., Sloma, I., Griscelli, A. B., Réa, D., Legros, L., Marfaing‐Koka, A., Bourhis, J.-H., Amé, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9182 · Cited by 68
Rothe, K., Porter, V., & Jiang, X. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030461 · Cited by 70
Mechanisms of resistance to BCR-ABL and other kinase inhibitors
Lamontanara, A. J., Akçok, E. B. G., Kuzyk, O., & Hantschel, O. D. (2012) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2012.12.009 · Cited by 71
“While the survival of disease perpetuating immature blasts is dependent on BCR-ABL signaling, persistent cells with stem-like properties survive upon BCR-ABL inhibition [67,68].”
BackgroundYang, H., Chennamaneni, L. R., Ho, M. W. T., Ang, S. H., Tan, E. S. W., Jeyaraj, D. A., Yeap, Y. S., Liu, B., Ong, E. H., Joy, J. K., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01714 · Cited by 65
DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia
Valent, P., Sadovnik, I., Ráčil, Z., Herrmann, H., Blatt, K., Cerny‐Reiterer, S., Eisenwort, G., Lion, T., Holyoake, T. L., & Mayer, J. (2014) · European Journal of Clinical Investigation · doi:10.1111/eci.12368 · Cited by 65
Tang, M., Gönen, M., Quintás‐Cardama, A., Cortes, J. E., Kantarjian, H. M., Field, C. R., Hughes, T. P., Branford, S., & Michor, F. (2011) · Blood · doi:10.1182/blood-2011-02-339267 · Cited by 65
Self-citationNon ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
Massimino, M., Stella, S., Tirrò, E., Romano, C., Pennisi, M. S., Puma, A., Manzella, L., Zanghì, A., Stagno, F., Raimondo, F. D., et al. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0805-1 · Cited by 66
“Moreover, it is now apparent that, despite complete inhibition of BCR-ABL1 kinase activity, TKIs are unable to eliminate quiescent Leukemic Stem Cells (LSCs) [4, 31, 32], as these cells are not “oncogene addicted” and therefore require alternative treatment strategies [32, 33].”
BackgroundAustin, R. J., Straube, J., Bruedigam, C., Pali, G., Jacquelin, S., Vu, T., Green, J., Gräsel, J., Lansink, L., Cooper, L., et al. (2020) · Leukemia · doi:10.1038/s41375-019-0638-y · Cited by 61
Selective elimination of leukemia stem cells: Hitting a moving target
Crews, L. A., & Jamieson, C. H. M. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.08.006 · Cited by 67
“Evidence indicates that LSC evasion of TKI-induced cell death is BCR–ABL1-independent [24,25], and likely requires aberrant activation of additional cell-intrinsic pathways regulating cell survival, self-renewal, as well as cell-extrinsic pathways that promote or interfere with interactions with supportive hematopoiet…”
BackgroundLin, L.-C., Yeh, C., Kuo, C., Lee, C., Yen, G., Wang, L.-S., Wu, C., Yang, W. V., & Wu, A. T. H. (2012) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf301981n · Cited by 66
Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia
Maia, R. C., Vasconcelos, F. D. C., de Souza, P. S., & Rumjanek, V. M. (2018) · Molecules · doi:10.3390/molecules23010119 · Cited by 63
“The study of interactions between TKIs and ABC transporters is important, especially in the field of development of new drugs able to overcome, or even inhibit, the interference of efflux transporters in the pharmacokinetics of drugs.”
BackgroundInfluentialLeukemia-Initiating Cells in T-Cell Acute Lymphoblastic Leukemia
Tan, S. H., Bertulfo, F. C., & Sanda, T. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00218 · Cited by 66
“Several studies have shown that signals from the bone marrow niche can dictate the survival of LICs and their responses to various types of treatment administered (80, 81).”
BackgroundSundaram, D. N. M., Jiang, X., Brandwein, J. M., Valencia‐Serna, J., Remant, K. C. B., & Uludağ, H. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.05.007 · Cited by 66
OCT1 and imatinib transport in CML: is it clinically relevant?
Watkins, D. B., Hughes, T. P., & White, D. L. (2015) · Leukemia · doi:10.1038/leu.2015.170 · Cited by 60
Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells
Hamad, A., Sahli, Z. T., Sabban, M. E., Mouteirik, M., & Nasr, R. (2013) · Stem Cells International · doi:10.1155/2013/724360 · Cited by 58
“Moreover, most CML patients in remission continue to show minimal residual disease detected by the quantitative real-time PCR analysis of peripheral blood or bone marrow [42].”
BackgroundShinohara, H., Kumazaki, M., Minami, Y., Ito, Y., Sugito, N., Kuranaga, Y., Taniguchi, K., Yamada, N. O., Otsuki, Y., Naoe, T., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.11.020 · Cited by 64
Salati, S., Salvestrini, V., Carretta, C., Genovese, E., Rontauroli, S., Zini, R., Rossi, C., Ruberti, S., Bianchi, E., Barbieri, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17706 · Cited by 60
“demonstrated that CML LSCs survive IM treatment independently of BCR-ABL kinase activity [4].”
BackgroundBaba, T., Naka, K., Morishita, S., Komatsu, N., Hirao, A., & Mukaida, N. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20130112 · Cited by 57
“Evidence is accumulating to indicate that LICs are relatively resistant to TKI therapy compared with mature leukemia cells (Corbin et al., 2011).”
BackgroundRole of STAT3 in Transformation and Drug Resistance in CML
Nair, R. R., Tolentino, J. H., & Hazlehurst, L. A. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00030 · Cited by 56
Metabolic alterations mediated by STAT3 promotes drug persistence in CML
Patel, S. B., Nemkov, T., Stefanoni, D., Benavides, G. A., Bassal, M. A., Crown, B. L., Matkins, V. R., Camacho, V., Kuznetsova, V., Hoang, A. T., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01315-0 · Cited by 56
Preleukemic Hematopoietic Stem Cells in Human Acute Myeloid Leukemia
Corces, M. R., Chang, H. Y., & Majeti, R. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00263 · Cited by 61
“However, while progenitor cells are highly sensitive to treatment (73), BCR-ABL-positive HSCs remain resistant (Figure 3) (74).”
BackgroundReddiconto, G., Toto, C., Palamà, I. E., Leo, S. D., de Luca, E., Matteis, S. D., Dini, L., Gambacorti-Passerini, C. B., Renzo, N. D., Maffia, M., et al. (2012) · Blood · doi:10.1182/blood-2011-06-361261 · Cited by 60
Levescot, A., Flamant, S., Basbous, S., Jacomet, F., Féraud, O., Bourgeois, E. A., Bonnet, M., Giraud, C., Roy, L., Barra, A., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2797 · Cited by 56
“Recent studies provide definite evidence for the kinase activity of BCR-ABL in CML stem cells and for its inhibition by imatinib mesylate without affecting their survival (5).”
BackgroundRaivola, J., Haikarainen, T., Abraham, B. G., & Silvennoinen, O. (2021) · Cancers · doi:10.3390/cancers13040800 · Cited by 55
Ianniello, Z., Sorci, M., Ginistrelli, L. C., Iaiza, A., Marchioni, M., Tito, C., Capuano, E., Masciarelli, S., Ottone, T., Attrotto, C., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04169-7 · Cited by 56
Molecular biology of chronic myeloid leukemia
Maru, Y. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02346.x · Cited by 60
An Update On Dual Src/Abl Inhibitors
Musumeci, F., Schenone, S., Brullo, C., & Botta, M. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.29 · Cited by 57
Kinase-inhibitor–insensitive cancer stem cells in chronic myeloid leukemia
Morotti, A., Panuzzo, C., Fava, C., & Saglio, G. N. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.867323 · Cited by 56
“This question was originally addressed in primary human CML cells [26].”
BackgroundIanniciello, A., Zarou, M. M., Rattigan, K. M., Scott, M. T., Dawson, A., Dunn, K. M., Brabcová, Z., Kalkman, E. R., Nixon, C., Michie, A. M., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd5016 · Cited by 58
Huuhtanen, J., Awad, S. A., Theodoropoulos, J., Forstén, S., Warfvinge, R., Dufva, O., Bouhlal, J., Dhapola, P., Duàn, H., Laajala, E., et al. (2023) · Leukemia · doi:10.1038/s41375-023-02074-w · Cited by 62
“As the quiescent CD34 + CD38-BCR-ABL1 + leukemic stem cells (LSCs) are known to be resistant to TKI treatment in vitro [12, 13], the immunological control or eradication of LSCs may contribute to successful TKI cessation.”
BackgroundBCR-ABL kinase is dead; long live the CML stem cell
Perl, A. E., & Carroll, M. P. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43605 · Cited by 54
Rovida, E., Peppicelli, S., Bono, S., Bianchini, F., Tusa, I., Cheloni, G., Marzi, I., Cipolleschi, M. G., Calorini, L., & Sbarba, P. D. (2014) · Cell Cycle · doi:10.4161/15384101.2014.964107 · Cited by 56
Perl, A. E., Kasner, M. T., Shank, D., Luger, S. M., & Carroll, M. P. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2346 · Cited by 53
“(3) Finally, it is possible that there is heterogeneity of signaling between different populations of tumor cells so that STI therapy may simply select for a sub-population of cells that do not require the targeted pathway to survive.(4) As none of these effects can be predicted by drug levels alone, direct pharmacody…”
Ali, M. A. M. (2016) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-016-0208-1 · Cited by 60
Oridonin Triggers Chaperon-mediated Proteasomal Degradation of BCR-ABL in Leukemia
Huang, H., Weng, H., Dong, B., Zhao, P., Zhou, H., & Qu, L. (2017) · Scientific Reports · doi:10.1038/srep41525 · Cited by 52
Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling
Kuepper, M. K., Bütow, M., Herrmann, O., Ziemons, J., Chatain, N., Maurer, A., Kirschner, M., Maié, T., Costa, I. G., Eschweiler, J., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0427-7 · Cited by 58
Lin, H., Rothe, K., Chen, M., Wu, A., Babaian, A., Yen, R., Zeng, J., Rüschmann, J., Petriv, O. I., O’Neill, K., et al. (2020) · Blood · doi:10.1182/blood.2019003636 · Cited by 55
Concise Review: Leukemia Stem Cells in Personalized Medicine
Guzmán, M. L., & Allan, J. N. (2014) · Stem Cells · doi:10.1002/stem.1597 · Cited by 57
Eide, C. A., & O’Hare, T. (2015) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-015-0248-3 · Cited by 50
Rothe, K., Babaian, A., Nakamichi, N., Chen, M., Chafe, S. C., Watanabe, A., Forrest, D. L., Mager, D. L., Eaves, C. J., Dedhar, S., et al. (2020) · Cell stem cell · doi:10.1016/j.stem.2020.04.005 · Cited by 53
Inhibition of STAT5: A therapeutic option in BCR-ABL1-driven leukemia
Berger, A., Sexl, V., Valent, P., & Moriggl, R. (2014) · Oncotarget · doi:10.18632/oncotarget.2465 · Cited by 55
Influence of Bone Marrow Microenvironment on Leukemic Stem Cells
Agarwal, P., & Bhatia, R. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.04.007 · Cited by 57
“renewing and leukemia-initiating capacity, which remain quiescent (Corbin et al., 2011; Warner et al., 2004).”
BackgroundRole of the β Common (βc) Family of Cytokines in Health and Disease
Hercus, T. R., Kan, W. L., Broughton, S. E., Tvorogov, D., Ramshaw, H. S., Sandow, J. J., Nero, T. L., Dhagat, U., Thompson, E. J., Shing, K. S. C. T., et al. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028514 · Cited by 56
IKK-dependent activation of NF-κB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1
Hsieh, M.-Y., & Etten, R. A. V. (2014) · Blood · doi:10.1182/blood-2014-01-547943 · Cited by 55
Wang, W., Pu, Q.-H., Lin, X., Liu, M.-Y., Wu, L., Wu, Q., Chen, Y., Liao, F., Zhu, J., & Jin, X. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.07.008 · Cited by 52
Genetic Mechanisms of Chronic Myeloid Leukemia Blastic Transformation
Skórski, T. (2012) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-012-0114-5 · Cited by 49
“In addition, the ability of TKIs to render residual CML-CP cells “inactive” rather than to eradicate them entirely suggests that CML-BP still may occur even in “responding” patients [3, 4].”
BackgroundSakuma, Y., Matsukuma, S., Nakamura, Y., Yoshihara, M., Koizume, S., Sekiguchi, H., Saito, H., Nakayama, H., Kameda, Y., Yokose, T., et al. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.102 · Cited by 49
Do we need more drugs for chronic myeloid leukemia?
Holyoake, T. L., & Helgason, G. V. (2014) · Immunological Reviews · doi:10.1111/imr.12234 · Cited by 53
“These results were replicated in the inducible BCR-ABL1 transgenic mouse model of CML and were confirmed by independent studies performed by the Deininger group (69, 70).”
BackgroundResultŠrůtová, K., Čuřík, N., Burda, P., Savvulidi, F. G., Silvestri, G., Trotta, R., Klamová, H., Pecherková, P., Sovová, Ž., Koblihova, J., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.193086 · Cited by 49
“CML LSCs survive and are able to re-initiate the disease after the discontinuation of TKI treatment in some patients.(6) The dysregulated epigenetic mechanisms previously described in CML involve microRNAs.”
BackgroundMolecular biology as a tool for the treatment of cancer
Anna, C. D. C. S., Ferreira, A. G., Soares, P. C., Tuji, F. M., Paschoal, E. H. A., Chaves, L. C., & Burbano, R. M. R. (2018) · Clinical and Experimental Medicine · doi:10.1007/s10238-018-0518-1 · Cited by 60
Lai, D., Chen, M., Su, J., Liu, X., Rothe, K., Hu, K., Forrest, D. L., Eaves, C. J., Morin, G. B., & Jiang, X. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan8735 · Cited by 47
Sulforaphane as a Promising Natural Molecule for Cancer Prevention and Treatment
Elkashty, O. A., & Tran, S. D. (2021) · Current Medical Science · doi:10.1007/s11596-021-2341-2 · Cited by 48
Advances in the treatment of chronic myeloid leukemia
Eiring, A. M., Khorashad, J. S., Morley, K., & Deininger, M. W. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-99 · Cited by 47
“hand, one could argue that the overall rate of CMR is lower than would be expected from the very rapid decline of leukemia burden, suggesting that in most patients the residual population of CML cells is beyond the reach of TKIs, consistent with the observation that primitive CML cells maintain viability despite TKI-i…”
ResultSelf-citationLi, F., He, B., Ma, X., Yu, S., Bhave, R. R., Lentz, S. R., Tan, K., Guzmán, M. L., Zhao, C., & Xue, H. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.08.001 · Cited by 48
“The majority of CML patients depend on lifetime TKI treatment, and substantial efforts have been devoted to identifying LSC-targeting drugs for use together with TKIs, aiming for a deeper molecular response and improving the outcome after TKI discontinuation.”
BackgroundInfluentialNovel therapeutic approaches in chronic myeloid leukemia
Yurttaş, N. Ö., & Eşkazan, A. E. (2020) · Leukemia Research · doi:10.1016/j.leukres.2020.106337 · Cited by 51
Eiring, A. M., Khorashad, J. S., Anderson, D. J., Yu, F., Redwine, H. M., Mason, C. C., Reynolds, K. R., Clair, P. M., Gantz, K. C., Zhang, T. Y., et al. (2015) · Leukemia · doi:10.1038/leu.2015.196 · Cited by 48
Self-citationMicro RNA s in myeloid malignancies
Gordon, J. E., Wong, J. J. L., & Rasko, J. E. J. (2013) · British Journal of Haematology · doi:10.1111/bjh.12364 · Cited by 51
“Despite the success of TK inhibitor therapy, the persistence of detectable disease (Ross et al, 2010) and recognition that the CML leukaemic stem cell is resistant to TK inhibition has renewed interest in its pathophysiology (Corbin et al, 2011), including the role of miRNAs (Table III).”
BackgroundDevelopment of an Effective Therapy for Chronic Myelogenous Leukemia
Woessner, D. W., Lim, C. S., & Deininger, M. W. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e318237e5b7 · Cited by 53
“It follows that therapies that only biochemically target BCR-ABL will be unable to eliminate CML stem cells.(71) Cytokines, chemokines, and the extracellular matrix, collectively referred to as the microenvironment, may activate signaling pathways involved in survival.”
BackgroundSelf-citationhsa-mir183/EGR1–mediated regulation of E2F1 is required for CML stem/progenitor cell survival
Pellicano, F., Park, L., Hopcroft, L. E. M., Shah, M., Jackson, L., Scott, M. T., Clarke, C. J., Sinclair, A., Abraham, S. A., Hair, A., et al. (2018) · Blood · doi:10.1182/blood-2017-05-783845 · Cited by 47
“ABL tyrosine kinase inhibitors (TKI) lead to long-term remission in the majority of CML patients, but approximately 50% of cases relapse when treatment is discontinued, as TKI are unable to fully eradicate quiescent stem/progenitor cells (SPC),(1-9) despite being able to inhibit BCR-ABL signaling in these cells.(6,9,1…”
Adaptive phenotypic modulations lead to therapy resistance in chronic myeloid leukemia cells
Baykal, S., Açıkgöz, E., Yavuz, A. S., Geyik, Ö. G., Ateş, H., Sezerman, O. U., Özsan, G. H., & Yüce, Z. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229104 · Cited by 45
“CML LSCs do not depend on BCR-Abl signaling for their survival and are free from oncogene addiction [33]; thus are able to survive under prolonged TKI treatment.”
BackgroundMak, D. H. F., Wang, R.-Y., Schober, W. D., Konopleva, M. Y., Cortes, J. E., Kantarjian, H. M., Andreeff, M., & Carter, B. Z. (2011) · Leukemia · doi:10.1038/leu.2011.285 · Cited by 44
Self-citationCarter, B. Z., Mak, P. Y., Mak, D. H. F., Ruvolo, V. R., Schober, W. D., McQueen, T. J., Cortes, J. E., Kantarjian, H. M., Champlin, R. E., Konopleva, M. Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5890 · Cited by 48
“The current standard of therapy for CML is inactive against quiescent CML stem/progenitor cells [2-6], which make up a small fraction of the CD34+ cell population that is responsible for disease recurrence upon drug discontinuation [7-9].”
BackgroundSelf-citationWu, L., Yu, J., Chen, R., Liu, Y., Lou, L., Wu, Y. C., Huang, L., Fan, Y., Gao, P., Huang, M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3317 · Cited by 43
“Furthermore, in addition to the Abl kinase mutations contributing to imatinib resistance, the accumulation of LSCs plays a critical role in CML relapse after imatinib therapy (4, 5).”
BackgroundSato, T., Goyama, S., Kataoka, K., Nasu, R., Tsuruta-Kishino, T., Kagoya, Y., Nukina, A., Kumagai, K., Kubota, N., Nakagawa, M. M., et al. (2014) · Oncogene · doi:10.1038/onc.2014.108 · Cited by 46
Novel approaches to therapy in CML
Bhatia, R. (2017) · Hematology · doi:10.1182/asheducation-2017.1.115 · Cited by 49
“Several studies have found that TKIs effectively inhibit kinase activity within LSCs and that LSC resistance is therefore BCR-ABL kinase independent.(6,7) These findings have had a huge impact in defining the direction of CML research over the last 15 years, and there is wide agreement that approaches to increase trea…”
BackgroundDendritic Cell-Based Immunotherapy for Myeloid Leukemias
Schürch, C. M., Riether, C., & Ochsenbein, A. F. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00496 · Cited by 46
“It is thought that CML LSCs are not completely addicted to BCR/ABL1, and several studies have shown survival of CML LSCs in the presence of Imatinib in vitro and in vivo [(28) and reviewed in Ref.”
BackgroundBencomo-Alvarez, A. E., Rubio, A. J., Olivas, I. M., Gonzalez, M. A., Ellwood, R. A., Fiol, C. R., Eide, C. A., Lara, J. J., Barreto‐Vargas, C., Jave‐Suárez, L. F., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01732-6 · Cited by 49
Self-citationAutophagy in Chronic Myeloid Leukaemia: Stem Cell Survival and Implication in Therapy
Helgason, G. V., Mukhopadhyay, A., Karvela, M., Salomoni, P., Calabretta, B., & Holyoake, T. L. (2013) · Current Cancer Drug Targets · doi:10.2174/15680096113139990088 · Cited by 46
“treatment that fully inhibits Bcr-Abl kinase activity [86, 87], indicating that combination therapy is needed to provide a cure for CML patients.”
BackgroundFrolova, O., Benito, J., Brooks, C. L., Wang, R., Korchin, B., Rowinsky, E. K., Cortes, J. E., Kantarjian, H. M., Andreeff, M., Frankel, A. E., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12978 · Cited by 41
“Moreover, the persistence of LSCs as a cause of relapse may occur in as many as 75% of patients after treatment discontinuation (Graham et al, 2002; Copland et al, 2006; Corbin et al, 2011).”
BackgroundSelf-citation
Metadata
- Authors
- Corbin, A. S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M. W., & Druker, B. J.
- Affiliations
- Howard Hughes Medical Institute (US)
- Oregon Health & Science University (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2011-01-04
- Volume
- 121
- Issue
- 1
- Pages
- 396-409
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3007128
- OpenAlex
- W2122224021
- Cited by
- 765
- References
- 47
- Citations by year
- 2026: 13 · 2025: 20 · 2024: 32 · 2023: 34 · 2022: 43 · 2021: 48 · 2020: 57 · 2019: 51 · 2018: 47 · 2017: 66 · 2016: 53 · 2015: 51 · 2014: 67 · 2013: 76 · 2012: 66
- FWCI
- 36.63
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense
- T.J. Martell Foundation
- Leukemia and Lymphoma Society
- National Heart, Lung, and Blood Institute (R01HL082978, HL082978-01)
- National Cancer Institute (R37CA065823)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- chronic myeloid leukemia, imatinib, BCR-ABL, leukemia stem cells, disease persistence, drug resistance, stem cell survival, CD34+CD38- cells, CD133, progenitor cells, oncogene addiction
- MeSH terms
- Imatinib Mesylate, Antineoplastic Agents, Benzamides, Cell Survival, Humans, Models, Biological, Piperazines, Pyrimidines, Neoplastic Stem Cells, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Cytokines, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Cell Proliferation, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.